A top chipmaker is surging on pre-tariff demand, a major insurer is crashing after a sharp forecast cut, and an edtech firm is pivoting into AI-driven therapy, sending its shares surging 74%. Here’s what’s moving the markets today.
We’re collecting testimonials from our readers!
If EliteTrade.Club has helped you become a better investor, just hit reply and tell us how.
If we feature your story, we’ll send you a $25 Chick-fil-A gift card as a thank-you.
Looking forward to hearing from you!
Earnings:
Taiwan Semiconductor Manufacturing Company Ltd. [TSM]: Premarket
UnitedHealth Group Incorporated [UNH]: Premarket
American Express Company [AXP]: Premarket
The Charles Schwab Corporation [SCHW]: Premarket
Marsh & McLennan Companies, Inc. [MMC]: Premarket
Blackstone Inc. [BX]: Premarket
Netflix, Inc. [NFLX]: Aftermarket
Independent Bank Corp. [INDB]: Aftermarket
Economic Reports:
Initial jobless claims (Apr 12): 8:30 am
Housing starts (March): 8:30 am
Building permits (March): 8:30 am
Philadelphia Fed manufacturing survey (April): 8:30 am
Fed Governor Michael Barr will speak at 11:45 am
🚨 No, it's not the publicly traded tech giant you might expect… Meet $MODE, the disruptor turning phones into potential income generators.
Mode saw 32,481% revenue growth, ranking them the #1 software company on Deloitte’s 2023 fastest-growing companies list.
📲 They’re pioneering "Privatized Universal Basic Income" powered by technology — not government, and their EarnPhone has already helped consumers earn over $325M!
Invest in their pre-IPO offering before their share price changes on May 1st.
*An intent to IPO is no guarantee that an actual IPO will occur. Please read the offering circular and related risks at invest.modemobile.com.
*The Deloitte rankings are based on submitted applications and public company database research.
Taiwan Semiconductor Manufacturing Co. (NYSE: TSM) posted stronger-than-expected earnings for the first quarter, as global clients rushed to secure advanced chips ahead of possible tariff hikes from the U.S.
The world’s largest contract chipmaker, which supplies industry leaders like Nvidia (NASDAQ: NVDA) and Apple (NASDAQ: AAPL), reported a net profit of NT$361.6 billion ($11.1 billion), beating the average analyst forecast of NT$346.8 billion.
This result follows a 42% surge in quarterly revenue, previously disclosed, driven by an uptick in demand for smartphones, laptops, and consumer electronics—particularly from U.S. buyers bracing for potential trade restrictions.
Investors are now zeroing in on TSMC’s guidance for 2025, which the company plans to release later today.
The outlook carries weight, especially after a rocky week for the chip sector.
New U.S. export curbs on Nvidia’s China-bound chips and a lackluster earnings report from ASML Holding (NASDAQ: ASML) have shaved $200 billion off industry valuations, casting shadows on semiconductor momentum.
Concerns are mounting over how escalating U.S.-China tensions—fueled by renewed trade war rhetoric—might curb global growth and tech consumption.
Economists are already scaling back projections, with uncertainty looming over iPhone sales, computing hardware, and broader tech infrastructure spending.
UnitedHealth Group (NYSE: UNH) shares are plunging this morning, dropping 20% in pre-market trading, after the company significantly lowered its full-year earnings guidance.
The Minneapolis-based health insurer now forecasts 2025 net earnings per share in the range of $24.65 to $25.15, a steep cut from its previous estimate of $28.15 to $28.65.
The sharp downgrade has erased over $100 billion in market capitalization in just a few hours.
The company attributed the guidance revision to a sharp and unexpected increase in medical service usage among older adults—a trend that caught its actuarial models off guard.
CEO Andrew Witty acknowledged the underperformance, stating the company is taking aggressive action to correct course and realign its long-term outlook.
UnitedHealth is also still navigating internal challenges following the tragic death of Brian Thompson, one of its senior executives, who was shot and killed outside an investor meeting in New York late last year.
The incident added a layer of instability to an already challenging period for the firm.
Want to know when to consider trading stocks like Apple and Walmart?
These Stock Hotsheets use 10 years of historical data to uncover key dates and trends—helping you trade with confidence
American Express (NYSE: AXP) reported first-quarter results that surpass Wall Street expectations, driven by sustained consumer spending momentum.
The financial services firm posted earnings per share of $3.64 on revenue of $16.97 billion, marking a 7% year-over-year increase.
These figures topped analyst projections, which had anticipated EPS of $3.47 and revenue of $16.94 billion.
Net interest income also edged past estimates, reaching $4.17 billion versus the expected $4.10 billion.
CEO Stephen Squeri noted that consumer activity during the first three months of 2025 remained robust and in some cases exceeded 2024 levels.
Despite economic uncertainties, the company reaffirmed its full-year guidance of 8% to 10% revenue growth and projected annual EPS between $15.00 and $15.50.
Shares of American Express are trading slightly higher this morning, climbing less than 1%. The stock, however, is still down around 15% year-to-date.
Investor confidence was buoyed last week after Bank of America upgraded the stock to a "buy" rating.
Analysts cited the firm’s affluent customer base as a key buffer against potential macroeconomic slowdowns or a possible recession.
The solid Q1 print reinforces that thesis, showing the company remains resilient amid a shifting financial landscape.
Baijiayun Group Ltd is growing 74% in premarket trading today after announcing a groundbreaking partnership with Beijing Xinlantian Education Technology to create AI-driven rehabilitation programs for children with autism.
The venture could position Baijiayun as a leading player in AI-powered healthcare solutions for neurodevelopmental disorders.
My Take: While still in early stages, Baijiayun's shift toward AI in healthcare is promising. In the long run, this could mark a meaningful growth vertical beyond its core edtech offerings. Keep a close watch on this stock.
Channel Therapeutics Corporation is a biotechnology company focused on developing and commercializing non-opioid pain therapies.
It is making headlines today after announcing a strategic merger with Ligand Pharmaceuticals' subsidiaries—Pelthos Therapeutics and LNHC—to form a newly branded company, Pelthos Therapeutics. The deal, valued at $50 million, will be supported by fresh funding from Ligand and investors led by Murchinson.
My Take: This merger gives Channel Therapeutics a fast-track path into commercial-stage biotech. Keep this company on your radar and monitor progress on the merger.
Treasure Global Inc. is a Malaysian tech firm. It is surging in premarket trading after announcing it has secured exclusive distribution rights for Mezzofy's digital coupon platform in Malaysia.
The partnership is expected to generate $2 million to $4 million in recurring annual revenue within the first year, driving strong investor interest.
My Take: This deal gives Treasure Global an edge in Southeast Asia’s booming e-commerce sector. Keep a close watch on how the deal progresses.
Discover the best days to consider trading top stocks like Apple, LULU, and Walmart.
These hotsheets are based on 10 years of historical data, giving you a clear edge. No confusing charts—just actionable trade opportunities.
Eli Lilly’s new oral drug helps patients lose 7.9% of their weight and lower blood sugar, sending shares sharply higher.
Truist’s profit takes a hit as trade policy uncertainty slows investment banking activity.
Kinder Morgan beats revenue expectations in the first quarter but falls slightly short on earnings.
Despite gains in intermodal shipping, CSX is struggling to offset falling coal revenue in the first quarter.
Alcoa manages a strong quarter by boosting income and navigating tariffs, though revenue continued to slide.
Rexford reaffirms its full-year core FFO guidance as first-quarter results come in ahead of expectations.
Weaker demand in North America causes Infosys to miss revenue estimates and lower its growth forecast.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
*Standard message/carrier rates may apply.
Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.